Interaction of serum vitamin B₁₂ and folate with *MTHFR* genotypes on risk of ischemic stroke

Xianhui Qin, MD, PhD, J. David Spence, MD, Jianping Li, MD, Yan Zhang, MD, Youbao Li, MD, Ningling Sun, MD, Min Liang, MD, Yun Song, MD, Yuanyuan Zhang, MD, Binyan Wang, MD, Xiaoshu Cheng, MD, Lianyou Zhao, MD, Xiaobin Wang, MD, ScD, Xiping Xu, MD, PhD, and Yong Huo, MD

Correspondence

Dr. Huo
huoyong@263.net.cn
or Dr. Xu
xipingxu126@126.com

Neurology® 2020;94:e1126-e1136. doi:10.1212/WNL.0000000000008932

Abstract

Objective

We evaluated the interaction of serum folate and vitamin B₁₂ with methylenetetrahydrofolate reductase (*MTHFR*) C677T genotypes on the risk of first ischemic stroke and on the efficacy of folic acid treatment in prevention of first ischemic stroke.

Methods

A total of 20,702 hypertensive adults were randomized to a double-blind treatment of daily enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone. Participants were followed up every 3 months.

Results

Median values of folate and B₁₂ concentrations at baseline were 8.1 ng/mL and 280.2 pmol/L, respectively. Over a median of 4.5 years, among those not receiving folic acid, participants with baseline serum B₁₂ or serum folate above the median had a significantly lower risk of first ischemic stroke (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.57–0.96), especially in those with *MTHFR* 677 CC genotype (wild-type) (HR, 0.49; 95% CI, 0.31–0.78). Folic acid treatment significantly reduced the risk of first ischemic stroke in participants with both folate and B₁₂ below the median (2.3% in enalapril-folic acid group vs 3.6% in enalapril-only group; HR, 0.62; 95% CI, 0.46–0.86), particularly in *MTHFR* 677 CC carriers (1.6% vs 4.9%; HR, 0.24; 95% CI, 0.11–0.55). However, TT homozygotes responded better with both folate and B₁₂ levels above the median (HR, 0.28; 95% CI, 0.10–0.75).

Conclusions

The risk of first ischemic stroke was significantly higher in hypertensive patients with low levels of both folate and B₁₂. Effect of folic acid treatment was greatest in patients with low folate and B₁₂ with the CC genotype, and with high folate and B₁₂ with the TT genotype.

From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Glossary

CI = confidence interval; CSPPT = China Stroke Primary Prevention Trial; HR = hazard ratio; IQR = interquartile range; MI = myocardial infarction; *MTHFR* = methylenetetrahydrofolate reductase; tHcy = total homocysteine.

Stroke is a major cause of death and disability worldwide.^{1,2} There is increasing interest in identifying novel modifiable risk factors to improve primary prevention of stroke and reduce the related severe disease burden.

Numerous prospective studies have shown a graded, independent association between total homocysteine (tHcy) and stroke.^{3–5} Folate, vitamin B₁₂, and vitamin B₆ deficiencies and reduced major enzyme (such as methylenetetrahydrofolate reductase [*MTHFR*]) activities in folate and homocysteine metabolism may inhibit the metabolism of homocysteine, thus increasing tHcy levels.⁶ Moreover, vitamin B₁₂ and folate have direct antioxidant, antithrombotic, and endothelium-protective effects, and have a major role in DNA synthesis or repair.^{7,8} Therefore, as expected, previous randomized trials have shown that folic acid therapy composed of folic acid, vitamin B₁₂, and vitamin B₆ reduced the risk of ischemic stroke.^{9–11} Furthermore, the beneficial effect on stroke was more pronounced in trials conducted in populations without folic acid fortification and with lower vitamin B₁₂ levels.¹⁰ This has led some physicians to think that in countries with folate fortification, only vitamin B₁₂ was necessary for homocysteine lowering to prevent stroke. More importantly, it appears that in the early randomized trials of B vitamins for stroke prevention, toxicity from cyanocobalamin among study participants with impaired renal function may have obscured the benefit of B vitamins.⁹ However, the joint effect of naturally occurring serum B₁₂ and folate, with *MTHFR* C677T genotypes, on the risk of first ischemic stroke, and on the efficacy of folic acid treatment in prevention of first ischemic stroke has not been fully investigated in previous studies.

Hypertension is one of the most important risk factors for stroke.^{12,13} As such, our current study aimed to address the above knowledge gap in hypertensive adults, using data from the China Stroke Primary Prevention Trial (CSPPT).¹⁴

Methods

Standard protocol approvals, registrations, and patient consents

The CSPPT was registered in clinicaltrials.gov (identifier: NCT00794885). The current study is a post hoc analysis of the CSPPT. The parent study (the CSPPT) and the current study were approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (FWA assurance number: FWA00001263). Informed consent was waived for the post hoc analysis.

Participants

Details regarding the study design and major results of the CSPPT have been reported elsewhere.¹⁴ Briefly, the CSPPT was

a multicommunity, randomized, double-blind, controlled trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in China. Eligible participants were men and women aged 45–75 years who had hypertension, defined as seated, resting systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at both the screening and recruitment visit, or who were on antihypertensive medication. The major exclusion criteria included history of physician-diagnosed stroke, myocardial infarction (MI), heart failure, post coronary revascularization, congenital heart disease, or current supplementation by folic acid, vitamin B₁₂, or vitamin B₆.

Procedures

Eligible participants, stratified by *MTHFR* C677T genotypes (CC [wild-type], CT, or TT), were randomly assigned, in a 1:1 ratio, to 1 of 2 treatment groups: a daily tablet containing 10 mg enalapril and 0.8 mg folic acid (the enalapril–folic acid group) or a daily tablet containing 10 mg enalapril only (the enalapril-only group).

During the trial period, concomitant use of other antihypertensive drugs (mainly calcium channel blockers or diuretics) was allowed, but not B vitamins. Participants were scheduled for follow-up every 3 months.

Laboratory assays

Serum folate and vitamin B₁₂ at baseline were measured by a commercial laboratory using a chemiluminescent immunoassay (New Industrial, Shenzhen, China). Serum tHcy (at both the baseline and the exit visit) and fasting lipids and glucose at baseline were measured using automatic clinical analyzers (Beckman Coulter, Brea, CA) at the core lab of the National Clinical Research Center for Kidney Disease (Nanfeng Hospital, Guangzhou, China). *MTHFR* C677T (rs1801133) polymorphisms were detected on an ABI PRISM 7900HT sequence detection system (Life Technologies, Carlsbad, CA) using the TaqMan assay.

Study outcomes

In the CSPPT, the primary outcome was first stroke (ischemic or hemorrhagic). However, folic acid reduced only ischemic stroke and did not affect hemorrhagic stroke.¹⁴ For that reason, the primary outcome for this study was a first ischemic stroke (fatal or nonfatal). The secondary outcomes included a first stroke (ischemic or hemorrhagic), excluding subarachnoid hemorrhage and silent stroke, and a composite of cardiovascular events consisting of cardiovascular death, MI, and stroke.

All the study outcomes were reviewed and adjudicated by an independent Endpoint Adjudication Committee, whose members were unaware of study group assignments.

Statistical analysis

Means (SD) and proportions were calculated for population characteristics in accordance with the combined baseline folate and B₁₂ levels (group 1: B₁₂ <280.2 pmol/L [median] and folate <8.1 ng/mL [median]; group 2: B₁₂ <280.2 pmol/L and folate ≥ 8.1 ng/mL; group 3: B₁₂ ≥280.2 pmol/L and folate <8.1 ng/mL; group 4: B₁₂ ≥280.2 pmol/L and folate ≥8.1 ng/mL). The hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of first ischemic stroke associated with the combined baseline folate and B₁₂ levels were estimated using Cox proportional hazards models in the enalapril-only group without and with adjustment for major covariates. Interactions of B₁₂ and folate subgroups with *MTHFR* C677T genotypes (CC [wild-type] vs CT or TT) were examined by including interaction terms into the Cox models. We further assessed the effect of folic acid treatment on the total population (participants from the enalapril-only group and the enalapril–folic acid group) on the prevention of first ischemic stroke according to different B₁₂ and folate strata by means of Cox proportional hazards regression both before and after adjustment for the major covariates.

As a post hoc analysis, correction for multiple hypothesis testing was not applied, and a 2-tailed $p < 0.05$ was considered statistically significant in all analyses. R software, version 3.4.3 (R-project.org/), was used to perform all statistical analyses.

Data availability

The data, analytic methods, and study materials that support the findings of this study will be available from the corresponding authors on request, after the request is submitted and formally reviewed and approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China.

Results

Study participants and baseline characteristics

In this study, a total of 20,499 participants (10,256 in the enalapril-only group and 10,243 in the enalapril–folic acid group) with baseline folate and B₁₂ measurements were included in the final analyses (figure e-1, doi.org/10.5061/dryad.s45jd1v).

Baseline characteristics of participants in the total population, the enalapril-only group, and the enalapril–folic acid group by baseline folate and B₁₂ level subgroupings (groups 1–4) are summarized in table e-1 (doi.org/10.5061/dryad.s45jd1v) and tables 1 and e-2 (doi.org/10.5061/dryad.s45jd1v), respectively. Median values of folate and B₁₂ concentrations were 8.1 ng/mL (interquartile range [IQR] 5.6–10.5) and 280.2 pmol/L (IQR 232.4–351.7), respectively, in the enalapril group. Compared with participants in groups 2–4 at baseline, participants in group 1 were older and had significantly higher body mass index, creatinine, and tHcy; lower total cholesterol, high-density lipoprotein cholesterol, and fasting glucose levels; a lower prevalence of self-reported diabetes; lower usage of

glucose-lowering drugs; and higher usage of antihypertensive drugs at baseline. However, all the differences had small magnitudes. Moreover, participants in group 1 were more likely to be smokers and TT genotype carriers than were the other 3 groups (table e-3, doi.org/10.5061/dryad.s45jd1v).

Relationship of baseline serum B₁₂ and folate with baseline tHcy levels in the enalapril-only group

Compared with participants with both lower B₁₂ and lower folate levels (group 1) at baseline, significantly lower tHcy levels were found in those with higher folate alone (group 2; β , -2.7; 95% CI, -3.1 to -2.3 μ mol/L), higher B₁₂ alone (group 3; β , -3.1; 95% CI, -3.5 to -2.7 μ mol/L), both higher B₁₂ and higher folate (group 4; β , -4.1; 95% CI, -4.6 to -3.7 μ mol/L), and higher B₁₂ or higher folate levels (groups 2–4; β , -3.3; 95% CI, -3.6 to -2.9 μ mol/L).

Similar results were found in participants with the *MTHFR* 677 CC, CT, or TT genotype (table e-4, doi.org/10.5061/dryad.s45jd1v).

Interaction of baseline serum B₁₂ and folate levels with *MTHFR* C677T genotypes on the risk of first ischemic stroke in the enalapril-only group

The median treatment duration was 4.5 years. Overall, there was no significant association of baseline B₁₂ or folate levels alone with the risk of first ischemic stroke (figure e-2 and table e-5, doi.org/10.5061/dryad.s45jd1v) in the enalapril-only group. To make our findings more applicable to clinical practice, folate and B₁₂ levels were both divided at the median to create a low and high category (figure e-5, doi.org/10.5061/dryad.s45jd1v).

Compared with participants in group 1 (both lower B₁₂ and lower folate levels at baseline), a lower risk of first ischemic stroke was found in those with higher folate alone (group 2: HR, 0.65; 95% CI, 0.45–0.93), higher B₁₂ alone (group 3: HR, 0.79; 95% CI, 0.57–1.07), both higher B₁₂ and higher folate (group 4: HR, 0.77; 95% CI, 0.55–1.09), or higher B₁₂ or higher folate levels (groups 2–4: HR, 0.74; 95% CI, 0.57–0.96) (table 2). Due to the similar risk reduction, we combined groups 2–4 together in the following analysis.

When participants were stratified by baseline tHcy levels, among those with lower (<12.5 μ mol/L [median]) tHcy levels, a significantly lower risk of first ischemic stroke was found in those with higher folate alone (group 2: HR, 0.38; 95% CI, 0.20–0.72), higher B₁₂ alone (group 3: HR, 0.53; 95% CI, 0.31–0.91), both higher B₁₂ and higher folate (group 4: HR, 0.55; 95% CI, 0.33–0.91), and higher B₁₂ or higher folate levels (groups 2–4: HR, 0.50; 95% CI, 0.32–0.77), compared with those in group 1. However, no significant association was found in participants with higher tHcy levels (table e-6, doi.org/10.5061/dryad.s45jd1v).

Table 1 Participant characteristics by baseline vitamin B₁₂ (median <280.2 vs ≥280.2 pmol/L) and folate (median <8.1 vs ≥8.1 ng/mL) subgroups in the enalapril-only group^a

Variables	Vitamin B ₁₂ and folate			
	Group 1: B ₁₂ <280.2 and folate <8.1	Group 2: B ₁₂ <280.2 and folate ≥8.1	Group 3: B ₁₂ ≥280.2 and folate <8.1	Group 4: B ₁₂ ≥280.2 and folate ≥8.1
No.	2,836	2,301	2,319	2,800
Male, n (%)	1,422 (50.1)	754 (32.8)	1,061 (45.8)	962 (34.4)
Age, y	60.4 ± 7.8	60.0 ± 7.5	60.0 ± 7.7	59.5 ± 7.2
Body mass index, kg/m ²	25.3 ± 3.5	24.6 ± 3.8	25.4 ± 3.6	24.5 ± 3.7
MTHFR C677T polymorphisms, n (%)				
CC	593 (20.9)	708 (30.8)	527 (22.7)	982 (35.1)
CT	1,289 (45.5)	1,178 (51.2)	1,158 (49.9)	1,402 (50.1)
TT	954 (33.6)	415 (18.0)	634 (27.4)	416 (14.8)
Current smoking	834 (29.4)	405 (17.6)	650 (28.0)	487 (17.4)
Blood pressure, mm Hg				
Baseline SBP	166.9 ± 20.4	165.8 ± 19.8	169.3 ± 21.4	166.1 ± 20.0
Baseline DBP	94.3 ± 12.3	92.9 ± 11.8	95.5 ± 12.0	93.5 ± 11.9
Mean SBP during treatment period	140.3 ± 11.6	139.7 ± 11.6	140.1 ± 11.5	139.3 ± 11.4
Mean DBP during treatment period	83.4 ± 7.8	82.6 ± 7.8	83.7 ± 7.7	82.6 ± 7.6
Self-reported hyperlipidemia	74 (2.6)	62 (2.7)	67 (2.9)	72 (2.6)
Self-reported diabetes	63 (2.2)	62 (2.7)	97 (4.2)	111 (4.0)
Laboratory results, mmol/L				
Total cholesterol	5.4 ± 1.1	5.4 ± 1.1	5.7 ± 1.2	5.6 ± 1.2
Triglycerides	1.7 ± 1.0	1.6 ± 0.9	1.8 ± 1.0	1.6 ± 0.9
HDL cholesterol	1.3 ± 0.4	1.4 ± 0.3	1.3 ± 0.4	1.4 ± 0.4
Fasting glucose	5.7 ± 1.3	5.8 ± 1.6	5.9 ± 1.8	5.9 ± 2.1
Folate, ng/mL	5.6 ± 1.4	11.2 ± 3.1	5.8 ± 1.4	11.7 ± 3.7
Total homocysteine, μmol/L	18.0 ± 12.3	13.4 ± 6.1	14.5 ± 8.0	11.9 ± 3.7
Creatinine, μmol/L	67.5 ± 23.2	63.9 ± 15.8	68.0 ± 18.3	64.4 ± 16.8
Vitamin B ₁₂ , pmol/L	226.8 ± 36.2	228.3 ± 37.2	378.8 ± 129.1	390.2 ± 119.1
Medication use, n (%)				
Antihypertensive drugs	1,365 (48.1)	1,014 (44.1)	1,173 (50.6)	1,219 (43.5)
Glucose-lowering drugs	23 (0.8)	30 (1.3)	48 (2.1)	50 (1.8)
Lipid-lowering drugs	19 (0.7)	21 (0.9)	20 (0.9)	24 (0.9)
Antiplatelet drugs	86 (3.0)	73 (3.2)	96 (4.1)	65 (2.3)

Abbreviations: DBP = diastolic blood pressure; HDL = high-density lipoprotein; *MTHFR* = methylenetetrahydrofolate reductase; SBP = systolic blood pressure.
^a For continuous variables, values are presented as mean ± SD.

When participants were stratified by the *MTHFR* C677T genotypes, a stronger association (groups 2–4 vs group 1) was found in those with CC genotype (wild-type) (HR, 0.49; 95% CI,

0.31–0.78; vs CT/TT genotype: HR, 0.83; 95% CI, 0.61–1.11; *p* interaction = 0.044) (tables 2 and e-7, doi.org/10.5061/dryad.s45jd1v), especially in those with higher (≥12.5 μmol/L) baseline

Table 2 Interaction of vitamin B₁₂ (median <280.2 vs ≥ 280.2 pmol/L) and folate (median <8.1 vs ≥8.1 ng/mL) with methylenetetrahydrofolate reductase (*MTHFR*) C677T genotypes on risk of first ischemic stroke in the enalapril-only group

Vitamin B ₁₂ and folate	No. of events/no. of patients (%)	Hazard ratio (95% CI) ^a	Adjusted hazard ratio (95% CI) ^a
All participants in the enalapril-only group			
Group 1: B₁₂ <280.2 and folate <8.1	102/2,836 (3.6)	1.00 (ref)	1.00 (Ref)
Groups 2–4: B₁₂ ≥280.2 or folate ≥8.1, or both	184/7,420 (2.5)	0.68 (0.53–0.86)	0.74 (0.57–0.96)
Group 2: B₁₂ <280.2 and folate ≥8.1	47/2,301 (2.0)	0.56 (0.39–0.79)	0.65 (0.45–0.93)
Group 3: B₁₂ ≥280.2 and folate <8.1	71/2,319 (3.1)	0.85 (0.63–1.15)	0.79 (0.57–1.07)
Group 4: B₁₂ ≥280.2 and folate ≥8.1	66/2,800 (2.4)	0.64 (0.47–0.87)	0.77 (0.55–1.09)
<i>MTHFR</i> C677T genotypes^b			
CC			
Group 1	29/593 (4.9)	1.00 (Ref)	1.00 (Ref)
Groups 2–4	51/2,217 (2.3)	0.46 (0.29–0.72)	0.49 (0.31–0.78)
CT/TT			
Group 1	73/2,243 (3.3)	1.00 (Ref)	1.00 (Ref)
Groups 2–4	133/5,203 (2.6)	0.77 (0.58–1.03)	0.83 (0.61–1.11)

Abbreviation: CI = confidence interval.
^a Adjusted for age, sex, *MTHFR* C677T genotypes, body mass index, systolic and diastolic blood pressure, study centers, creatinine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, fasting glucose, smoking, and alcohol drinking status at baseline, as well as time-averaged systolic and diastolic blood pressure during the treatment period.
^b *p* Interaction between *MTHFR* C677T genotypes (CC vs CT/TT) and group (1 vs 2–4) = 0.044.

tHcy levels (*p* interaction = 0.014) (tables 2 and e-6, doi.org/10.5061/dryad.s45jd1v).

Similar results were found when folate levels were divided at quartile 1 (5.6 ng/mL) (table e-8, doi.org/10.5061/dryad.s45jd1v), as well as for first stroke (table e-9, doi.org/10.5061/dryad.s45jd1v), and the composite of cardiovascular events (table e-10, doi.org/10.5061/dryad.s45jd1v).

Effect of baseline serum B₁₂ and folate levels with *MTHFR* C677T genotypes on the efficacy of folic acid treatment in preventing first ischemic stroke among the total population

Folic acid treatment significantly reduced tHcy levels. As expected, a greater reduction of tHcy was observed in participants in group 1 (both lower B₁₂ and lower folate levels) compared with those in groups 2–4 (table 3). Consistently, folic acid treatment significantly reduced the risk of first ischemic stroke by 38% in participants in group 1 (HR, 0.62; 95% CI, 0.46–0.86) (figure 1 and table 4).

When participants were stratified by the *MTHFR* C677T genotypes, among participants with CC genotype, the beneficial effect was greater in participants in group 1 (HR, 0.24; 95% CI, 0.11–0.55; vs groups 2–4: HR, 0.72; 95% CI, 0.46–1.10; *p* interaction = 0.016) (figures 2 and e-3, doi.org/10.5061/dryad.s45jd1v, table 4). Similar trends were found in those with higher

(≥12.5 μmol/L [median]) or lower (<12.5 μmol/L) tHcy levels (table e-11, doi.org/10.5061/dryad.s45jd1v).

Among participants with the CT or TT genotype, a beneficial effect was observed in participants in group 1 with lower (<12.5 μmol/L) tHcy levels (HR, 0.44; 95% CI, 0.21–0.92). Nevertheless, that benefit is not established in groups 2–4 with higher (≥12.5 μmol/L) tHcy levels (HR, 0.77; 95% CI, 0.54–1.08) or in group 1 with higher (≥12.5 μmol/L) tHcy levels (HR, 0.94; 95% CI, 0.63–1.41) (table e-11, doi.org/10.5061/dryad.s45jd1v).

However, among those with the 677 TT genotype, the greatest benefit of folic acid treatment was found in participants in group 4, those participants with both higher B₁₂ and higher folate levels at baseline (HR, 0.28; 95% CI, 0.10–0.75) (figures 2 and e-3 [doi.org/10.5061/dryad.s45jd1v] and table 4). The trends were similar in those with higher (≥12.5 μmol/L) or lower (<12.5 μmol/L) tHcy levels (table e-11, doi.org/10.5061/dryad.s45jd1v).

Similar results were found for first stroke (table e-12, doi.org/10.5061/dryad.s45jd1v) or composite of cardiovascular events (table e-13, doi.org/10.5061/dryad.s45jd1v).

Discussion

A recent meta-analysis¹⁵ reported that folic acid therapy would be beneficial for prevention of stroke, particularly in countries

Table 3 Total homocysteine (μmol/L) at baseline and after treatment by vitamin B₁₂ (B₁₂, median <280.2 vs ≥ 280.2 pmol/L) and folate (median <8.1 vs ≥8.1 ng/mL) subgroups and methylenetetrahydrofolate reductase (*MTHFR*) C677T genotypes in the total population

	Enalapril	Enalapril-folic acid	p Value
Total population			
Group 1: B₁₂ <280.2 and folate <8.1			
Baseline	18.0 (12.3) [2,793]	17.9 (12.0) [2,742]	0.820
End of intervention	16.5 (9.3) [2,407]	13.9 (7.0) [2,364]	<0.001
Change ^a	-1.2 (8.7) [2,370]	-3.9 (10.4) [2,329]	<0.001
Groups 2-4: B₁₂ ≥280.2 or folate ≥8.1, or both			
Baseline	13.2 (6.2) [7,335]	13.1 (5.6) [7,379]	0.521
End of intervention	13.8 (7.3) [6,082]	12.5 (6.0) [6,078]	<0.001
Change ^a	0.7 (6.2) [6,007]	-0.5 (6.1) [6,018]	<0.001
<i>MTHFR</i> 677 CC genotype			
Group 1: B₁₂ <280.2 and folate <8.1			
Baseline	13.9 (5.6) [579]	13.8 (7.0) [549]	0.712
End of intervention	14.3 (5.3) [494]	12.9 (5.5) [468]	<0.001
Change ^a	0.8 (4.8) [481]	-0.8 (4.4) [462]	<0.001
Groups 2-4: B₁₂ ≥280.2 or folate ≥8.1, or both			
Baseline	12.1 (3.6) [2,197]	12.2 (3.8) [2,217]	0.839
End of intervention	13.0 (4.4) [1,798]	12.2 (5.8) [1,812]	<0.001
Change ^a	0.9 (3.7) [1,779]	0.1 (5.0) [1,799]	<0.001
<i>MTHFR</i> 677 CT genotype			
Group 1: B₁₂ <280.2 and folate <8.1			
Baseline	14.8 (6.9) [1,268]	14.7 (6.1) [1,254]	0.676
End of intervention	15.0 (7.3) [1,083]	13.3 (4.7) [1,082]	<0.001
Change ^a	0.4 (5.4) [1,066]	-1.4 (4.9) [1,062]	<0.001
Groups 2-4: B₁₂ ≥280.2 or folate ≥8.1, or both			
Baseline	12.5 (4.6) [3,700]	12.6 (4.2) [3,725]	0.544
End of intervention	13.3 (6.2) [3,074]	12.3 (4.7) [3,067]	<0.001
Change ^a	0.9 (4.8) [3,040]	-0.2 (4.4) [3,034]	<0.001
<i>MTHFR</i> 677 TT genotype			
Group 1: B₁₂ <280.2 and folate <8.1			
Baseline	24.7 (17.1) [946]	24.6 (16.6) [939]	0.880
End of intervention	19.7 (12.2) [830]	15.4 (9.5) [830]	<0.001
Change ^a	-4.5 (12.3) [823]	-8.9 (15.1) [823]	<0.001
Groups 2-4: B₁₂ ≥280.2 or folate ≥8.1, or both			
Baseline	16.5 (10.3) [1,438]	16.0 (9.1) [1,437]	0.179
End of intervention	16.3 (11.6) [1,210]	13.4 (8.5) [1,199]	<0.001
Change ^a	-0.3 (10.8) [1,188]	-2.5 (9.9) [1,185]	<0.001

Values are means (SD) (no. of participants with available data).

^a Total homocysteine after treatment minus that at baseline.

Figure 1 Kaplan-Meier curves for first ischemic stroke by treatment group and B₁₂/folate subgroups

Kaplan-Meier curves of cumulative hazards for first ischemic stroke by treatment group in participants with (A) both lower vitamin B₁₂ (median <280.2 pmol/L) and lower folate (median <8.1 ng/mL) levels or (B) higher vitamin B₁₂ (≥280.2 pmol/L) or higher folate levels (≥8.1 ng/mL) or both. CI = confidence interval; HR = hazard ratio.

where folic acid fortification is not in place. However, in countries where folic acid fortification exists, the main nutritional determinant of tHcy is B₁₂, and biochemical B₁₂ deficiency and metabolic B₁₂ deficiency (inadequate active B₁₂) are common,¹⁶ so it may be important to add vitamin B₁₂ to folic acid therapy, even in countries with folic acid fortification. We found that patients with low levels of both folate and B₁₂ had significantly higher risk of first ischemic stroke, especially in those with the *MTHFR* 677 CC genotype (wild-type), suggesting that folic acid therapy alone would not be optimal for

reduction of stroke. Furthermore, in patients with low levels of both folate and B₁₂, folic acid treatment reduced first ischemic stroke for all such patients by 38%, and by 76% in those with the *MTHFR* 677 CC genotype.

The prospective relationship of serum B₁₂ or folate with the risk of stroke is controversial. Van Guelpen et al.¹⁷ suggested a protective role for folate in hemorrhagic stroke, and found no obvious association between B₁₂ and either hemorrhagic or ischemic stroke in a prospective, nested case-referent study. Giles et al.¹⁸ reported an inverse association between serum folate and ischemic stroke in black but not in white patients. The Kuopio Ischaemic Heart Disease Risk Factor Study¹⁹ showed that men in the highest third of serum folate concentrations had an adjusted relative risk (RR) for any stroke of 0.35 (95% CI, 0.14–0.87), compared with men in the lowest third. Only one previous case-cohort study²⁰ comprising 779 controls and 188 incident cases of cerebral ischemia (ischemic stroke or TIA) by Weikert et al.²⁰ evaluated the combined effect of folate and B₁₂ on stroke. Consistent with our study, the authors found that the combination of low B₁₂ with low folate levels significantly increased the risk of cerebral ischemia. However, this study had rather limited stroke cases, and did not consider possible confounding factors such as *MTHFR* C677T genotypes, blood pressure control, and renal function.

A previous meta-analysis that focused on genetic studies and prospective studies concluded that a 3 μmol/L homocysteine decrease could reduce the risk of stroke by 24%.⁴ Consistent with this prediction, in the current study, among participants in the enalapril-only group, a tHcy reduction of 3.3 μmol/L was seen between group 1 (both lower B₁₂ and lower folate levels) and groups 2–4 (higher B₁₂ or higher folate levels or both), and was associated with a 26% stroke risk reduction. However, the stroke risk reduction between group 1 and groups 2–4 was mainly found in participants with lower tHcy levels. In fact, in addition to its effect on tHcy levels, folate has direct antioxidant and antithrombotic effects, and can ameliorate endothelial dysfunction.⁷ B₁₂ insufficiency is also associated with a reduction in glutathione and serum total antioxidant capacity.⁸ More importantly, B₁₂ and folate play a fundamental role in DNA synthesis or repair. These results suggest that the increased stroke risk may be associated with both lower vitamin (folate or B₁₂) and higher tHcy levels. Among those with higher tHcy levels in the enalapril-only group without additional supplementation, the relatively higher folate or B₁₂ levels were still insufficient to fully correct for deficiencies and excesses in vitamin and tHcy levels.

MTHFR is a key enzyme involved in folate metabolism. The common *MTHFR* gene 677C→T polymorphism is associated with reduced enzyme activity (30% reduction in CT and 70% reduction in TT), resulting in decreased folate and increased tHcy levels.⁶ Our previous study suggested that baseline tHcy was associated with an increased risk of first stroke among participants with the CC/CT genotype, but not among those with the TT genotype.²¹ Moreover, folic acid intervention

Table 4 Effect of folic acid therapy on first ischemic stroke by vitamin B₁₂ (median <280.2 vs ≥280.2 pmol/L) and folate (median <8.1 vs ≥8.1 ng/mL) subgroups, and methylenetetrahydrofolate reductase (*MTHFR*) C677T genotypes, in the total population

Vitamin B ₁₂ and folate	Enalapril, n (%)	Enalapril-folic acid, n (%)	Hazard ratio (95% CI)	Adjusted hazard ratio (95% CI) ^a	p for interaction ^a
Total population					
Group 1: B₁₂ <280.2 and folate <8.1	102 (3.6)	64 (2.3)	0.64 (0.46–0.87)	0.62 (0.46–0.86)	Ref
Groups 2–4: B₁₂ ≥280.2 or folate ≥8.1, or both	184 (2.5)	156 (2.1)	0.84 (0.68–1.04)	0.84 (0.67–1.05)	0.130
<i>MTHFR</i> C677T genotypes					0.055 ^b
CC					
Group 1	29 (4.9)	9 (1.6)	0.32 (0.15–0.68)	0.24 (0.11–0.55)	Ref
Groups 2–4	51 (2.3)	37 (1.7)	0.72 (0.47–1.10)	0.72 (0.46–1.10)	0.016
CT/TT					
Group 1	73 (3.3)	55 (2.5)	0.76 (0.53–1.07)	0.78 (0.55–1.10)	Ref
Groups 2–4	133 (2.6)	119 (2.3)	0.89 (0.70–1.14)	0.88 (0.68–1.13)	0.582
<i>MTHFR</i> 677 TT genotype					
Groups 1–3	68 (3.4)	51 (2.6)	0.76 (0.53–1.09)	0.79 (0.55–1.15)	Ref
Group 4	15 (3.6)	6 (1.4)	0.38 (0.15–0.97)	0.28 (0.10–0.75)	0.044

Abbreviation: CI = confidence interval.

^a Adjusted for age, sex, *MTHFR* C677T genotypes, body mass index, systolic and diastolic blood pressure, study centers, creatinine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, fasting glucose, smoking, and alcohol drinking status at baseline, as well as mean systolic and diastolic blood pressure during the treatment period.

^b Three-way interaction test: p interaction of *MTHFR* C677T genotypes (CC vs CT/TT), group (1 vs 2–4), and folic acid treatment.

mainly reduced the stroke risk in participants with the TT genotype and lower tHcy levels.²¹ Accordingly, our current study found that a greater tHcy reduction between group 1 (both lower B₁₂ and lower folate levels) and groups 2–4 (higher B₁₂ or higher folate levels or both) in those with the *MTHFR* 677 TT genotype did not lead to a greater risk reduction of stroke risk. More importantly, among *MTHFR* 677 TT carriers, the greatest benefit of folic acid treatment was in those with higher baseline levels of both B₁₂ and folate (group 4) regardless of baseline tHcy levels. We speculate that TT carriers may require a higher dose of folic acid, in addition to B₁₂ supplementation, to further lower the stroke risk.

Our previous study also found that folic acid treatment significantly reduced stroke risk in participants with CC/CT genotypes and higher tHcy levels.²¹ Our current study further suggested that among those with higher tHcy levels, the greatest benefit of folic acid treatment still occurred in those with the CC genotype and low levels of both folate and B₁₂ (group 1), while a beneficial trend was also observed in participants in groups 2–4 (higher B₁₂ or higher folate levels or both) regardless of genotype. The lack of benefit from folic acid treatment in participants in group 1 with the CT/TT genotype may be due to the inability of folic acid treatment to fully correct the tHcy levels in those groups. However, even among those with lower tHcy levels, folic acid treatment significantly reduced the stroke

risk in group 1 (both lower B₁₂ and lower folate levels), especially in those with the CC genotype. 5,10-Methylene-THF is involved in the conversion of deoxyuridylate monophosphate to deoxythymidylate monophosphate, and low levels of 5,10-methylene-THF can lead to an increased ratio of deoxyuridine monophosphate to deoxythymidine monophosphate, inducing uracil misincorporation.²² DNA damage has been associated with increased cardiovascular disease.^{23,24} The enzyme *MTHFR* irreversibly reduces 5,10-methylene-THF to 5-methyl-THF. We hypothesize that when B₁₂ and folate are both insufficient, a less active form of *MTHFR* could possibly lead, all other factors being equal, to an accumulation of 5,10-methylene-THF, which leads to a presumably protective effect against DNA damage.²⁵ As such, *MTHFR* 677 CC carriers are possibly more sensitive to the increase of tHcy and insufficiency of folate and B₁₂, and thereby benefit more from folic acid treatment. Consistently, among participants in group 1 (low levels of both folate and B₁₂), the higher ischemic stroke risk was found in participants who were *MTHFR* CC carriers (4.9% vs 3.3% in CT or TT carriers) (table 2) in our current study. These results indicate that the levels of both folate and B₁₂ and tHcy should be considered in the prediction and prevention of stroke.

Our previous meta-analysis of randomized trials lends further support to our current findings. We found that among trials conducted in populations without folic acid fortification, the

Figure 2 Folic acid therapy effect on first ischemic stroke by B₁₂/folate subgroups and methylenetetrahydrofolate reductase (*MTHFR* 677) genotypes (CC/TT)

Effect of folic acid therapy on first ischemic stroke by vitamin B₁₂ (median <280.2 vs ≥280.2 pmol/L) and folate (median <8.1 vs ≥8.1 ng/mL) subgroups and *MTHFR* C677T genotypes (CC and TT genotype) in the total population. *Group 1: B₁₂ <280.2 pmol/L and folate <8.1 ng/mL; group 2: B₁₂ <280.2 pmol/L and folate ≥8.1 ng/mL; group 3: B₁₂ ≥280.2 pmol/L and folate <8.1 ng/mL; group 4: B₁₂ ≥280.2 pmol/L and folate ≥8.1 ng/mL; adjusted for age, sex, body mass index, systolic and diastolic blood pressure, study centers, creatinine, total cholesterol, triglycerides, HDL cholesterol, fasting glucose, smoking and alcohol drinking status at baseline, and mean systolic and diastolic blood pressure during the treatment period. CI = confidence interval.

benefit of folic acid therapy in stroke prevention was mainly found in trials of populations with lower baseline B₁₂ levels (<283.4 pmol/L: RR, 0.78; 95% CI, 0.68–0.89; vs ≥283.4 pmol/L: RR, 1.00; 95% CI, 0.86–1.16; *p* interaction = 0.049).¹⁰ However, due to the apparent toxicity of cyanocobalamin among patients with impaired renal function,^{9,26} the potential benefits of a combined treatment of methylcobalamin and folic acid should be further investigated in future studies.⁹

Inadequate folate intake and B₁₂ insufficiency are prevalent in most countries without folic acid fortification. Even in the era of post folic acid fortification and widespread use of vitamin supplementation, there is substantial variability in blood folate levels within the US population and across racial/ethnic groups.²⁷ Although biochemical B₁₂ deficiency is usually defined as a serum B₁₂ <150 pmol/L, metabolic B₁₂ deficiency is common among patients with a serum B₁₂ <248 pmol/L.^{16,26} Our study suggests that higher doses of folic acid should be used to ensure adequate doses for persons with the *MTHFR* 677 TT genotype, and B₁₂ (probably as methylcobalamin) should be combined with folic acid to maximize reduction of stroke, even in countries with folic acid fortification.

The prevalence of the 677 CT and TT genotypes of *MTHFR* was much higher in this Chinese population than previously reported in other populations. We found that 27% had CC, 49% had CT, and 24% had the TT genotype. In contrast, in a study population mainly of European origin, Spence et al.²⁸ reported that 40.4% had CC, 46.6% had CT, and only 13% had TT genotypes. This may account for the much higher prevalence of hyperhomocysteinemia in China than in other populations. Yang et al.²⁹ reported a Chinese population prevalence of tHcy >15 μmol/L of 27.5%. In contrast, in a French population-based study,³⁰ the prevalence of tHcy >15 μmol/L was only 9.6% in men and 3.2% in women. The higher prevalence of the T allele in our population may have made it possible to observe the differences in response to folic acid that we observed among the *MTHFR* genotypes.

Our study had some limitations. First, this is a post hoc secondary analysis that did not take multiple testing into consideration; therefore, additional research is needed to further investigate and confirm our findings and determine an optimal dosage and strategy for folic acid and B₁₂ therapy that is based on an individual's *MTHFR* 677 genotype. Second, the CSPPT used a fixed dose of folic acid (0.8 mg daily). While this is believed to be a reasonable dose according to previous studies,^{10,31} the relatively low dose of folic acid made it possible to recognize that a higher dose folate is probably needed for patients with the TT genotype. Third, our study was conducted in Chinese hypertensive patients, and more studies are needed to confirm our findings in other populations with similar and different characteristics. Another limitation of the CSPPT is the lack of classification of ischemic stroke subtypes, such as large artery disease, small artery disease, or cardioembolic stroke. In addition, we did not have folate or B₁₂ measurements at the cellular level. Therefore, our results are merely hypothesis-generating. Confirmation of our findings in an independent population is essential.

The combination of lower folate and lower B₁₂ levels significantly increased the risk of first ischemic stroke in hypertensive patients. Folic acid treatment reduced the first ischemic stroke risk for such patients by 38%. Effect of folic acid treatment was greatest in patients with low folate and B₁₂ with the CC genotype, and with high folate and B₁₂ with TT genotypes. This finding suggests that folic acid fortification (which delivers ~400 μg/d of folic acid) may not be adequate for TT homozygous patients, so treatment with B₁₂ alone may not be sufficient for prevention of stroke in countries with folate fortification.

These results are applicable to individuals receiving B vitamin therapy to lower tHcy for preventive purposes, and may also aid health care administrators in developing appropriate strategies that are based on specific population characteristics when implementing or creating guidelines for mandatory folic acid or B₁₂ fortification.

Study funding

The study was supported by funding from the following: the National Key Research and Development Program (2016YFE0205400, 2018ZX09739, 2018ZX09301034003); the National Natural Science Foundation of China (81730019, 81973133); the Science and Technology Planning Project of Guangzhou, China (201707020010); the Science, Technology and Innovation Committee of Shenzhen (JSGG20170412155639040, GJHS20170314114526143); the Economic, Trade and Information Commission of Shenzhen Municipality (20170505161556110, 20170505160926390); and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2017J009). The funders had no role in the design and/or conduct of the study (data collection, management, analysis, and interpretation); the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Disclosure

X. Qin reports grants from the National Natural Science Foundation of China (81730019, 81973133) and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2017J009). J. Spence is a consultant to Amgen and Orphan Technologies and has received lecture fees from Pfizer and Bristol-Myers-Squibb. J. Li, Y. Zhang, Y. Li, N. Sun, M. Liang, Y. Song, Y. Zhang, B. Wang, X. Cheng, L. Zhao, and X. Wang report no disclosures relevant to the manuscript. X. Xu reports grants from the National Key Research and Development Program (2016YFE0205400, 2018ZX09739, 2018ZX09301034003), the Science and Technology Planning Project of Guangzhou, China (201707020010), the Science, Technology and Innovation Committee of Shenzhen (JSGG20170412155639040, GJHS20170314114526143), and the Economic, Trade and Information Commission of Shenzhen Municipality (20170505161556110, 20170505160926390). Y. Huo reports no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Publication history

Received by *Neurology* June 8, 2020. Accepted in final form September 19, 2020.

Appendix Authors

Name	Location	Role	Contribution
Xianhui Qin, MD, PhD	Nanfang Hospital, Southern Medical University	Author	Study concept and design, acquisition of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, data management and statistical analysis

Appendix (continued)

Name	Location	Role	Contribution
J. David Spence, MD	University of Western Ontario	Author	Study concept and design, drafting of the manuscript, critical revision of the manuscript for important intellectual content
Jianping Li, MD	Peking University First Hospital	Author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content
Yan Zhang, MD	Peking University First Hospital	Author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content
Youbao Li, MD	Nanfang Hospital, Southern Medical University	Author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content, data management and statistical analysis
Ningling Sun, MD	Peking University People's Hospital	Author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content
Min Liang, MD	Nanfang Hospital, Southern Medical University	Author	Study concept and design, critical revision of the manuscript for important intellectual content
Yun Song, MD	China Agricultural University	Author	Study concept and design, critical revision of the manuscript for important intellectual content
Yuanyuan Zhang, MD	Nanfang Hospital, Southern Medical University	Author	Study concept and design, critical revision of the manuscript for important intellectual content
Binyan Wang, MD	Anhui Medical University	Author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content
Xiaoshu Cheng, MD	Second Affiliated Hospital, Nanchang University	Author	Study concept and design, critical revision of the manuscript for important intellectual content

Continued

Appendix (continued)

Name	Location	Role	Contribution
Lianyou Zhao, MD	The Fourth Military Medical University	Author	Study concept and design, critical revision of the manuscript for important intellectual content
Xiaobin Wang, MD, ScD	Johns Hopkins University Bloomberg School of Public Health	Author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content
Xiping Xu, MD, PhD	Nanfeng Hospital, Southern Medical University	Corresponding author	Study concept and design, critical revision of the manuscript for important intellectual content
Yong Huo, MD	Peking University First Hospital	Corresponding author	Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content

References

- GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1151–1210.
- Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics: 2018 update: a report from the American Heart Association. *Circulation* 2018;137:e67–e492.
- Huang X, Li Y, Li P, et al. Association between percent decline in serum total homocysteine and risk of first stroke. *Neurology* 2017;89:2101–2107.
- Wald D, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a metaanalysis. *BMJ* 2002;325:1202.
- Qin X, Huo Y. H-type hypertension, stroke and diabetes in China: opportunities for primary prevention. *J Diabetes* 2016;8:38–40.
- Stanger O, Herrmann W, Pietrzik K, et al. DACH-LIGA homocysteine (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. *Clin Chem Lab Med* 2003;41:1392–1403.
- Verhaar MC, Stroes E, Rabelink TJ. Folate and cardiovascular disease. *Arterioscler Thromb Vasc Biol* 2002;22:6–13.
- UK, Kalita J, Singh SK, Rahi SK. Oxidative stress markers in vitamin B12 deficiency. *Mol Neurobiol* 2017;54:1278–1284.
- Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. *Lancet Neurol* 2017;16:750–760.
- Zhao M, Wu G, Li Y, et al. Meta-analysis of folic acid efficacy trials in stroke prevention: insight into effect modifiers. *Neurology* 2017;88:1830–1838.
- Qin X, Li J, Spence JD, et al. Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. *Stroke* 2016;47:2805–2812.
- Fan F, Yuan Z, Qin X, et al. Optimal systolic blood pressure levels for primary prevention of stroke in general hypertensive adults: findings from the CSPPT (China Stroke Primary Prevention Trial). *Hypertension* 2017;69:697–704.
- Song Y, Xu B, Xu R, et al. Independent and joint effect of brachial-ankle pulse wave velocity and blood pressure control on incident stroke in hypertensive adults. *Hypertension* 2016;68:46–53.
- Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. *JAMA* 2015;313:1325–1335.
- Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental vitamins and minerals for CVD prevention and treatment. *J Am Coll Cardiol* 2018;71:2570–2584.
- Spence JD. Metabolic vitamin B12 deficiency: a missed opportunity to prevent dementia and stroke. *Nutr Res* 2016;36:109–116.
- Van Guelpen B, Hultdin J, Johansson I, et al. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. *Stroke* 2005;36:1426–1431.
- Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. *Stroke* 1995;26:1166–1170.
- Virtanen JK, Voutilainen S, Happonen P, et al. Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study. *Eur J Cardiovasc Prev Rehabil* 2005;12:369–375.
- Weikert C, Dierkes J, Hoffmann K, et al. B vitamin plasma levels and the risk of ischemic stroke and transient ischemic attack in a German cohort. *Stroke* 2007;38:2912–2918.
- Zhao M, Wang X, He M, et al. Homocysteine and stroke risk: modifying effect of methylenetetrahydrofolate reductase C677T polymorphism and folic acid intervention. *Stroke* 2017;48:1183–1190.
- Boccia S, Hung R, Ricciardi G, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. *Am J Epidemiol* 2008;167:505–516.
- Izzotti A. DNA damage and alterations of gene expression in chronic-degenerative diseases. *Acta Biochim Pol* 2003;50:145–154.
- Federici C, Botto N, Manfredi S, Rizza A, Del Fiandra M, Andreassi MG. Relation of increased chromosomal damage to future adverse cardiac events in patients with known coronary artery disease. *Am J Cardiol* 2008;102:1296–1300.
- Roest M, van der Schouw YT, Grobbee DE, et al. Methylenetetrahydrofolate reductase 677 C/T genotype and cardiovascular disease mortality in postmenopausal women. *Am J Epidemiol* 2001;153:673–679.
- Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. *JAMA* 2011;306:2610–2611.
- Yang Q, Cogswell ME, Hamner HC, et al. Folic acid source, usual intake, and folate and vitamin B-12 status in US adults: national Health and Nutrition Examination Survey (NHANES) 2003–2006. *Am J Clin Nutr* 2010;91:64–72.
- Spence JD, Barnett PA, Hegele RA, Marian AJ, Freeman D, Malinow MR. Plasma homocyst(e)ine, but not MTHFR genotype, is associated with variation in carotid plaque area. *Stroke* 1999;30:969–973.
- Yang B, Fan S, Zhi X, et al. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. *Nutrients* 2014;7:74–90.
- Nabi H, Bochud M, Glaes J, et al. Association of serum homocysteine with major depressive disorder: results from a large population-based study. *Psychoneuroendocrinology* 2013;38:2309–2318.
- Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. *Arch Intern Med* 2001;161:695–700.